Full Text
Cost-Utility Analysis of First-Line Regimen Between Cisplatin Plus Pemetrexed and Carboplatin Plus Paclitaxel In Advanced Non-Squamous Non-Small-Cell Lung Cancer in Thailand

Abstract

Authors

P Tongpak

Back to Volume 17, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×